National Institute of Allergy & Infectious Diseases (NIAID)

302 articles with National Institute of Allergy & Infectious Diseases (NIAID)

• Emmes Will Support Development of a New Universal Flu Vaccine for The National Institute of Allergy and Infectious Diseases

  12/2/2019

  The Company's Contract with Digital Infuzion Adds New Dimension to its Long NIAID History

• ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

  11/21/2019

  Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.

• IDT Biologika Awarded New Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases

  11/5/2019

  IDT Biologika announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity contract no. HHSN272201800011I to provide process development activities and production of a vaccine against the Respiratory Syncytial Virus.

• BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine

  10/23/2019

  The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health

• PBL gains approval to advance next generation anthrax vaccine to Phase 1 clinical trial

  10/22/2019

  Porton Biopharma Ltd has announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase.

• Tesamorelin Study Results on NAFLD Published in Lancet HIV

  10/11/2019

  Theratechnologies Inc. is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease in HIV were published in the Lancet HIV.

• Versatope Awarded up to $17.9M for a Universal Influenza Vaccine

  9/25/2019

  The award is through the Broad Agency Announcement (BAA) program to advance Versatope's universal influenza vaccine candidate.

• Progentec Diagnostics Awarded SBIR Fast-Track Grant to Develop Immune Mediator-Based Blood Tests for Clinical Disease Activity in Lupus (SLE)

  7/26/2019

  In-development laboratory tests will inform concurrent and future clinical disease activity

• BostonGene Announces Partnership with National Institutes of Health

  7/23/2019

  Precision Medicine Studies Underway to Enable Dynamic Monitoring of Disease Progression and Response to Treatment

• Bolder BioTechnology Receives NIH Grant to Advance Development of Novel Treatments for Acute Radiation Syndrome

  7/18/2019

  The grant is a joint research project between Bolder BioTechnology and Indiana University School of Medicine (Indianapolis, IN)

• Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses

  7/15/2019

  LHF-535, Kineta's lead biodefense asset, is a novel once-daily oral antiviral drug currently being evaluated in Phase 1 safety trials in healthy volunteers.

• NIH Awards Grant to Enable Biosciences to Develop Improved Lyme Disease Test

  7/11/2019

  The Centers for Disease Control and Prevention (CDC) estimates that approximately 300,000 people will be infected with Lyme disease each year in the United States.

• LamdaGen and Arisan Therapeutics Receive a $2 Million NIH SBIR Phase II Grant to Develop a Dual Rapid Point-of-Care Test for Acute Dengue and Zika Viral Infections

  6/26/2019

  The L’AuRa platform enables robust diagnostic testing that is simple, compact and cost effective with no moving parts.

• Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology

  6/25/2019

  NIAID to Study Use of ENHANZE® Technology with Broadly Neutralizing Antibodies for Development of New HIV Treatments

• New $22 Million Project Targets Deadly Viruses

  4/4/2019

  Five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.

• IDT Biologika Awarded 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases

  10/17/2018

  The total funding could be up to $80 million over the course of the contract if all project milestones are met.

• TechnoVax Awarded $1.5 Million NIH Grant to Further Develop a Universal VLP-Based Influenza Vaccine

  9/12/2018

  TechnoVax, Inc. has received a two-year $1,481,000 SBIR-II grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH).

• 

  Emergent BioSolutions Buys PaxVax for $270 Million

  8/10/2018

  Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.

• Major Lupus Stem Cell Study Receives Additional Funding from the National Institutes of Health

  7/10/2018

  Lupus Foundation of America and the National Institute of Allergy and Infectious Diseases to co-fund an innovative clinical study that could generate progress towards new treatments

• NIAID Director Dr. Anthony Fauci to discuss progress made in the development of a universal flu vaccine at National Press Club Headliners Luncheon July 18

  6/14/2018

  This past year's flu season killed more children than any other non-pandemic year on record, according to data released by the Centers for Disease Control and Prevention (CDC) earlier this year.